Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Prepopik

Last reviewed on RxList: 8/24/2018
Prepopik Side Effects Center

Last reviewed on RxList 8/24/2018

Prepopik (sodium picosulfate, magnesium oxide, and anhydrous citric acid) for Oral Solution is a stimulant laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. The most common side effects from Prepopik were:

Tell your doctor if you have symptoms of loss of too much body fluid (dehydration) while taking Prepopik including vomiting that prevents you from keeping down the additional prescribed amounts of clear liquids that you must drink after taking Prepopik, dizziness, or urinating less often than normal.

Prepopik is supplied as a powder, and is reconstituted with cold water right before use. Each of 2 packets contains 16.1 g of powder: 10 mg sodium picosulfate, 3.5 g magnesium oxide, and 12 g anhydrous citric acid. The first dose is administered in the evening before the colonoscopy, and the second dose is administered the next morning prior to the colonoscopy. Other drugs may interact with Preopik. Tell your doctor all medications you use. Prepopik should be used during pregnancy only if clearly needed. It is not known if Prepopik passes into breast milk. Women should talk with their doctors about taking Prepopik before breastfeeding.

Our Prepopik Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Super Tips to Boost Digestive Health: Bloating, Constipation, and More See Slideshow
Prepopik Professional Information

SIDE EFFECTS

The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling:

  • Serious Fluid and Electrolyte Abnormalities [see WARNINGS AND PRECAUTIONS]
  • Cardiac Arrhythmias [see WARNINGS AND PRECAUTIONS]
  • Seizures [see WARNINGS AND PRECAUTIONS]
  • Use in Patients with Renal Impairment [see WARNINGS AND PRECAUTIONS]
  • Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis [see WARNINGS AND PRECAUTIONS]
  • Use in Patients with Significant Gastrointestinal Disease [see WARNINGS AND PRECAUTIONS]
  • Aspiration [see WARNINGS AND PRECAUTIONS]
  • Risk of Vomiting and Other Gastrointestinal Complications with Ingestion of Undissolved Powder [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.

In randomized, multicenter, controlled clinical trials, nausea, headache, and vomiting were the most common adverse reactions (>1%) following Prepopik administration. The patients were not blinded to the study drug. Since abdominal bloating, distension, pain/cramping, and watery diarrhea are known to occur in response to colon cleansing preparations, these effects were documented as adverse events in the clinical trials only if they required medical intervention (such as a change in study drug or led to study discontinuation, therapeutic or diagnostic procedures, met the criteria for a serious adverse event), or showed clinically significant worsening during the study that was not in the frame of the usual clinical course, as determined by the investigator.

Prepopik was compared for colon cleansing effectiveness with a preparation containing two liters (2L) of polyethylene glycol plus electrolytes solution (PEG + E) and two 5-mg bisacodyl tablets, all administered the day before the procedure. Table 1 displays the most common adverse reactions in Study 1 and Study 2 for the Prepopik Split-Dose and Day-Before dosing regimens, respectively, each as compared to the comparator preparation.

Table 1: Treatment-Emergent Adverse Reactions observed in at Least (>1%) of Patients using the Split-Dose Regimen and Day-Before Regimen **

Adverse Reaction Study 1: Split-Dose Regimen Study 2: Day-Before Regimen
PREPOPIK
(N=305)
n (% = n/N)
2L PEG+E* with 2 x 5-mg bisacodyl tablets
(N=298)
n (% = n/N)
PREPOPIK
(N=296)
n (% = n/N)
2L PEG+E* with 2 x 5-mg bisacodyl tablets
(N=302)
n (% = n/N)
Nausea 8 (2.6) 11 (3.7) 9 (3.0) 13 (4.3)
Headache 5 (1.6) 5 (1.7) 8 (2.7) 5 (1.7)
Vomiting 3 (1.0) 10 (3.4) 4 (1.4) 6 (2.0)
* 2L PEG + E = two liters polyethylene glycol plus electrolytes solution.
**abdominal bloating, distension, pain/cramping, and watery diarrhea not requiring an intervention were not collected

Electrolyte Abnormalities

In general, Prepopik was associated with numerically higher rates of abnormal electrolyte shifts on the day of colonoscopy compared to the preparation containing 2L of PEG + E plus two x 5-mg bisacodyl tablets (Table 2). These shifts were transient in nature and numerically similar between treatment arms at the Day 30 visit.

Table 2: Shifts from Normal Baseline to Outside the Normal Range at Day 7 and Day 30

Laboratory Parameter (direction of change) Visit Study 1: Split-Dose Regimen Study 2: Day-Before Regimen
PREPOPIK 2L PEG+E with 2x 5 mg bisacodyl tablets PREPOPIK 2L PEG+E with 2x 5 mg bisacodyl tablets
n/N (%) n/N (%)
Potassium (low) Day of Colonoscopy 19/260 (7.3) 11/268 ( 4.1 ) 13/274 (4.7) 13/271 (4.8)
24-48 hours 3/302 (1.0) 2/294 (0.7) 3/287 (1.0) 5/292 (1.7)
Day 7 11/285 (3.9) 8/279 (2.9) 6/276 (2.2) 14/278 (5.0)
Day 30 11/284 (3.9) 8/278 (2.9) 7/275 (2.5) 8/284 (2.8)
Sodium (low) Day of Colonoscopy 11/298 (3.7) 3/295 (1.0) 3/286 (1.0) 3/295 (1.0)
24-48 hours 1/303 (0.3) 1/295 (0.3) 1/288 (0.3) 1/293 (0.3)
Day 7 2/300 (0.7) 1/292 (0.3) 1/285 (0.4) 1/291 (0.3)
Day 30 2/299( 0.7) 3/291 (1.0) 1/284( 0.4) 1/296 (0.3)
Chloride (low) Day of Colonoscopy 11/301 (3.7) 1/298 (0.3) 3/287 (1.0) 0/297 (0.0)
24-48 hours 1/303 (0.3) 0/295 (0.0) 2/288 (0.7) 0/293 (0.0)
Day 7 1/303 (0.3) 3/295 (1.0) 0/285 (0.0) 0/293 (0.0)
Day 30 2/302 (0.7) 3/294 (1.0) 0/285 (0.0) 0/298 (0.0)
Magnesium (high) Day of Colonoscopy 34/294 (11.6) 0/294 (0.0) 25/288 (8.7) 1/289 (0.3)
24-48 hours 0/303 (0.0) 0/295 (0.0) 0/288 (0.0) 0/293 (0.0)
Day 7 0/297 (0.0) 1/291 (0.3) 1/286 (0.3) 1/285 (0.4)
Day 30 1/296 (0.3) 2/290 (0.7) 0/286 (0.0) 0/290 (0.0)
Calcium (low) Day of Colonoscopy 2/292 (0.7) 1/286 (0.3) 0/276 (0.0) 2/282 (0.7)
24-48 hours 0/303 (0.0) 0/295 (0.0) 0/288 (0.0) 0/293 (0.0)
Day 7 0/293 (0.0) 1/283 (0.4) 0/274 (0.0) 0/278 (0.0)
Day 30 0/292 (0.0) 1/282 (0.4) 0/274 (0.0) 1/283 (0.4)
Creatinine (high) Day of Colonoscopy 5/260 (1.9) 13/268 (4.9) 12/266 (4.5) 16/270 (5.9)
24-48 hours 1/303 (0.3) 0/295 (0.0) 0/288 (0.0) 0/293 (0.0)
Day 7 10/264 (0.4) 13/267 (4.8) 10/264 (3.8) 10/265 (3.8)
Day 30 11/264 (4.2) 14/265(5.3) 18/264 (6.8) 10/272 (3.7)
eGFR (low) Day of Colonoscopy 22/221 (10.0) 17/214 (7.9) 26/199 (13.1) 25/224 (11.2)
24-48 hours 76/303 (25.1) 72/295 (24.4) 82/288 (28.5) 62/293 (21.2)
Day 7 22/223 (10.0) 17/213 (8.0) 11/198 (5.6) 28/219 (12.8)
Day 30 24/223(10.8) 21/211 (10.0) 21/199 (10.6) 24/224 (10.7)

Pediatrics

In the pediatric patients aged 9 to 16 years who received Prepopik, the most common adverse reactions (> 5%) were nausea, vomiting, and abdominal pain [see Clinical Trials]. Electrolytes abnormalities were observed in pediatric patients similar to those seen in adults. Three patients had abnormally low glucose levels (40 to 47 mg/dL). Two patients received Prepopik and one received the comparator (PEG). The abnormal values occurred at the colonoscopy visit for one patient (Prepopik) and at the 5-day follow up visit for the other two patients (Prepopik and PEG). All three patients were asymptomatic.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of other oral formulations of sodium picosulfate, magnesium oxide and anhydrous citric acid similar to Prepopik. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity: rash, urticaria, purpura, and anaphylaxis [see CONTRAINDICATIONS]

Gastrointestinal: abdominal pain, diarrhea, fecal incontinence, aphthoid ileal ulcers, ischemic colitis [see WARNINGS AND PRECAUTIONS]

Neurologic: generalized tonic-clonic seizures with and without hyponatremia in epileptic patients [see WARNINGS AND PRECAUTIONS].

Read the entire FDA prescribing information for Prepopik (Sodium Picosulfate, Magnesium Oxide, and Anhydrous Citric Acid) for Oral Solution)

QUESTION

Pancreatitis is inflammation of an organ in the abdomen called the pancreas. See Answer
Related Resources for Prepopik

© Prepopik Patient Information is supplied by Cerner Multum, Inc. and Prepopik Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW